However, in the detection of aggressive cancer (Gleason score of ≥ 8 or clinical stage was advanced [T4 or N + or M +]), there was significant risk correlation between serum DHEAS levels and aggressive prostate cancer detection risk. Here, SULT2A1 is linked to prostate carcinoma.